A5035070931- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Monoclonal and Polyclonal Antibodies Research
- Phagocytosis and Immune Regulation
- Semiconductor materials and devices
- Blood Coagulation and Thrombosis Mechanisms
- Multiple Myeloma Research and Treatments
- Banking Sector Performance and Management
- Gastric Cancer Management and Outcomes
- Immunodeficiency and Autoimmune Disorders
- Smart Agriculture and AI
- Brain Metastases and Treatment
- Gastrointestinal Tumor Research and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Leaf Properties and Growth Measurement
- Viral-associated cancers and disorders
- Neutropenia and Cancer Infections
Indira Gandhi Delhi Technical University for Women
2022
Infant
2022
University of Virginia
2017-2021
University Hospitals Seidman Cancer Center
2020-2021
University of Wisconsin–Madison
2015-2016
Allogeneic hematopoietic cell transplantation (HCT) is a standard therapy for patients with intermediate to high-risk acute myeloid leukemia (AML) and associated improved long-term disease-free survival. Disparity exists in access HCT among different patient populations requires further study. In this study, we compared rates AML regions the state of Virginia identified geographic socioeconomic factors likelihood receiving HCT. We conducted retrospective, cohort study 18 74 years age...
Immune checkpoint inhibition is part of standard systemic management for many advanced malignancies. Toxicities from this treatment approach are unpredictable, though usually reversible with per established guidelines. Some patients suffer major morbidity and treatment-related mortality these agents in an unpredictable manner. Cardiac neurologic complications rare, but can result serious clinical consequences.We describe the presentation, management, outcomes eight sequential cases combined...
Abstract The Bcl-2 inhibitor venetoclax has yielded exceptional clinical responses in chronic lymphocytic leukemia (CLL). However, de novo resistance can result failure to achieve negative minimal residual disease and predicts poor treatment outcomes. Consequently, additional proapoptotic drugs, such as inhibitors of Mcl-1 Bcl-xL, are development. By profiling antiapoptotic proteins using flow cytometry, we find that leukemic B cells recently emigrated from the lymph node (CD69+/CXCR4Low)...
Modern day machine learning aims to categorize data based on developed models and predict future outcomes according these models. Today Machine Learning finds its application in various fields such as facial recognition, speech medical diagnosis for example predicting potential heart failure, sentiment analysis, product recommendations etc. This paper proposes 3 classification efficiently the Iris flower species. The proposed model uses Exploratory Data Analysis (EDA) analyse pre-process...
BackgroundWhile HCT provides the best chance for cure eligible patients with AML, barriers limit number able to receive HCT. Virginia (VA) has some of wealthiest and poorest counties in country. We hypothesize that there are geographic variations rate estimated unmet need AML VA. Understanding differences may help improve access HCT.MethodsAll aged 20-74 years diagnosed 2013-2015 were identified by VA Department Health classified residence into 8 regions: Southwest, Southside, Valley,...
Peripheral Blood Transplant (PBT) accounted for three-quarters of the Hematopoietic Cell (HCT) from unrelated donors in past decade, which indicates it has largely replaced Bone Marrow (BMT) as preferred graft source. This shift occurred due to evidence suggesting faster neutrophil and platelet engraftment with former. However, clinical favoring PBT other outcomes is inconclusive. Although meta-analyses have compared BMT related donors, no such analysis been conducted donor procedures. Our...
Responses to ibrutinib (IBR) or venetoclax (VEN) in Chronic Lymphocytic Leukemia (CLL) Mantle Cell Lymphoma (MCL) are often partial. We reported synergistic toxicity for the IBR+VEN combination CLL/MCL ex vivo and initiated an trial MCL (NCT02419560). However, we noted variable de novo resistance even vivo, this has been found patients (Tam et al., 2018). also that microenvironmental agonists (CpG-ODN, sCD40L, IL10; "agonist mix") rapidly induce (Jayappa 2017).Here show multi-drug tolerance...
Abstract Responses to ibrutinib (IBR) or venetoclax (VEN) in Chronic Lymphocytic Leukemia (CLL) Mantle Cell Lymphoma (MCL) are often partial. We reported synergistic toxicity for the IBR+VEN combination CLL/MCL ex vivo and initiated an trial MCL (NCT02419560). However, we noted variable de novo resistance even vivo, this has been found patients (Tam et al., 2018). also that microenvironmental agonists (CpG-ODN, sCD40L, IL10; “agonist mix”) rapidly induce (Jayappa 2017). Here show multi-drug...